Date: March 19, 2026 | 8 am ET, 12 pm GMT

Preventing HIV infection during pregnancy and breastfeeding is essential to eliminating vertical transmission. Long-acting pre-exposure prophylaxis (PrEP) is approved for individuals at increased risk of HIV acquisition, including pregnant and breastfeeding women (PBFW). In this HIVE webinar, representatives from the ministries of health in Zambia and Eswatini will share insights from implementing long-acting injectable PrEP options — lenacapavir (LEN) and cabotegravir (CAB-LA) for PBFW. The session will highlight implementation strategies, demand-creation approaches, early successes, and perspectives from a recipient of care.